FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112804584> ?p ?o ?g. }

• W2112804584 endingPage "326" @default.
• W2112804584 startingPage "318" @default.
• W2112804584 abstract "Abstract 3-Bromopyruvate (3-BrPA) is an alkylating agent and a well-known inhibitor of energy metabolism. Rapamycin is an inhibitor of the serine/threonine protein kinase mTOR. Both 3-BrPA and rapamycin show chemopreventive efficacy in mouse models of lung cancer. Aerosol delivery of therapeutic drugs for lung cancer has been reported to be an effective route of delivery with little systemic distribution in humans. In this study, 3-BrPA and rapamycin were evaluated in combination for their preventive effects against lung cancer in mice by aerosol treatment, revealing a synergistic ability as measured by tumor multiplicity and tumor load compared treatment with either single-agent alone. No evidence of liver toxicity was detected by monitoring serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzymes. To understand the mechanism in vitro experiments were performed using human non–small cell lung cancer (NSCLC) cell lines. 3-BrPA and rapamycin also synergistically inhibited cell proliferation. Rapamycin alone blocked the mTOR signaling pathway, whereas 3-BrPA did not potentiate this effect. Given the known role of 3-BrPA as an inhibitor of glycolysis, we investigated mitochondrial bioenergetics changes in vitro in 3-BrPA–treated NSCLC cells. 3-BrPA significantly decreased glycolytic activity, which may be due to adenosine triphosphate (ATP) depletion and decreased expression of GAPDH. Our results demonstrate that rapamycin enhanced the antitumor efficacy of 3-BrPA, and that dual inhibition of mTOR signaling and glycolysis may be an effective therapeutic strategy for lung cancer chemoprevention. Cancer Prev Res; 8(4); 318–26. ©2015 AACR." @default.
• W2112804584 created "2016-06-24" @default.
• W2112804584 creator A5009548740 @default.
• W2112804584 creator A5011165903 @default.
• W2112804584 creator A5014024059 @default.
• W2112804584 creator A5026984704 @default.
• W2112804584 creator A5048127064 @default.
• W2112804584 creator A5052167281 @default.
• W2112804584 creator A5061594020 @default.
• W2112804584 date "2015-03-31" @default.
• W2112804584 modified "2023-10-16" @default.
• W2112804584 title "Enhanced Antitumor Activity of 3-Bromopyruvate in Combination with Rapamycin <i>In Vivo</i> and <i>In Vitro</i>" @default.
• W2112804584 cites W1519480055 @default.
• W2112804584 cites W1564553363 @default.
• W2112804584 cites W1565276921 @default.
• W2112804584 cites W1967980682 @default.
• W2112804584 cites W1983538557 @default.
• W2112804584 cites W1985162677 @default.
• W2112804584 cites W1986749538 @default.
• W2112804584 cites W2017121383 @default.
• W2112804584 cites W2024822044 @default.
• W2112804584 cites W2036691369 @default.
• W2112804584 cites W2038056833 @default.
• W2112804584 cites W2069559454 @default.
• W2112804584 cites W2084839831 @default.
• W2112804584 cites W2103820559 @default.
• W2112804584 cites W2107498355 @default.
• W2112804584 cites W2107998933 @default.
• W2112804584 cites W2113305329 @default.
• W2112804584 cites W2116293130 @default.
• W2112804584 cites W2126537035 @default.
• W2112804584 cites W2134864870 @default.
• W2112804584 cites W2140276705 @default.
• W2112804584 cites W2144437266 @default.
• W2112804584 cites W2145529521 @default.
• W2112804584 cites W2147028601 @default.
• W2112804584 cites W2166226393 @default.
• W2112804584 cites W2166583179 @default.
• W2112804584 cites W2168434875 @default.
• W2112804584 cites W2168633127 @default.
• W2112804584 cites W2170984340 @default.
• W2112804584 doi "https://doi.org/10.1158/1940-6207.capr-14-0142" @default.
• W2112804584 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6004825" @default.
• W2112804584 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25644152" @default.
• W2112804584 hasPublicationYear "2015" @default.
• W2112804584 type Work @default.
• W2112804584 sameAs 2112804584 @default.
• W2112804584 citedByCount "19" @default.
• W2112804584 countsByYear W21128045842016 @default.
• W2112804584 countsByYear W21128045842017 @default.
• W2112804584 countsByYear W21128045842018 @default.
• W2112804584 countsByYear W21128045842019 @default.
• W2112804584 countsByYear W21128045842020 @default.
• W2112804584 countsByYear W21128045842021 @default.
• W2112804584 countsByYear W21128045842022 @default.
• W2112804584 countsByYear W21128045842023 @default.
• W2112804584 crossrefType "journal-article" @default.
• W2112804584 hasAuthorship W2112804584A5009548740 @default.
• W2112804584 hasAuthorship W2112804584A5011165903 @default.
• W2112804584 hasAuthorship W2112804584A5014024059 @default.
• W2112804584 hasAuthorship W2112804584A5026984704 @default.
• W2112804584 hasAuthorship W2112804584A5048127064 @default.
• W2112804584 hasAuthorship W2112804584A5052167281 @default.
• W2112804584 hasAuthorship W2112804584A5061594020 @default.
• W2112804584 hasBestOaLocation W21128045841 @default.
• W2112804584 hasConcept C121608353 @default.
• W2112804584 hasConcept C126322002 @default.
• W2112804584 hasConcept C150903083 @default.
• W2112804584 hasConcept C181199279 @default.
• W2112804584 hasConcept C185592680 @default.
• W2112804584 hasConcept C190283241 @default.
• W2112804584 hasConcept C20251656 @default.
• W2112804584 hasConcept C207001950 @default.
• W2112804584 hasConcept C2776256026 @default.
• W2112804584 hasConcept C502942594 @default.
• W2112804584 hasConcept C55493867 @default.
• W2112804584 hasConcept C71924100 @default.
• W2112804584 hasConcept C86554907 @default.
• W2112804584 hasConcept C86803240 @default.
• W2112804584 hasConcept C96232424 @default.
• W2112804584 hasConcept C98274493 @default.
• W2112804584 hasConceptScore W2112804584C121608353 @default.
• W2112804584 hasConceptScore W2112804584C126322002 @default.
• W2112804584 hasConceptScore W2112804584C150903083 @default.
• W2112804584 hasConceptScore W2112804584C181199279 @default.
• W2112804584 hasConceptScore W2112804584C185592680 @default.
• W2112804584 hasConceptScore W2112804584C190283241 @default.
• W2112804584 hasConceptScore W2112804584C20251656 @default.
• W2112804584 hasConceptScore W2112804584C207001950 @default.
• W2112804584 hasConceptScore W2112804584C2776256026 @default.
• W2112804584 hasConceptScore W2112804584C502942594 @default.
• W2112804584 hasConceptScore W2112804584C55493867 @default.
• W2112804584 hasConceptScore W2112804584C71924100 @default.
• W2112804584 hasConceptScore W2112804584C86554907 @default.
• W2112804584 hasConceptScore W2112804584C86803240 @default.
• W2112804584 hasConceptScore W2112804584C96232424 @default.
• W2112804584 hasConceptScore W2112804584C98274493 @default.
• W2112804584 hasIssue "4" @default.

• next